Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury

References

• The Multi-Society Task Force Report on Persistent Vegetative State. Medical aspects of the persistent vegetative state. I. New England Journal of Medicine 1994; 330: 1499–1508
   PubMed Web of Science ®Google Scholar
• Giacino JT, et al. The minimally conscious state. Definition and diagnostic criteria. Neurology 2002; 58: 349–353
   PubMed Web of Science ®Google Scholar
• Gennarelli TA, Thibault LE, Graham DI. Diffuse axonal injury: An important form of traumatic brain damage. The Neuroscientist 1998; 4: 202–215
   Web of Science ®Google Scholar
• Adams JH, Graham DI, Jennet B. The neuropathology of the vegetative state after an acute brain insult. Brain 2000; 123: 1327–1338
   PubMed Web of Science ®Google Scholar
• Menon DK, Owen AM, et al. Cortical processing in persistent vegetative state. The Lancet 1998; 352: 200
   PubMed Web of Science ®Google Scholar
• Laureys S, Faymonville ME, Degueldre C, Del Fiore G, Damas P, Lambermont B, Jannsens N, Aerts J, Franck G, Luxen A, et al. Auditory processing in the vegetative state. Brain 2000; 123: 1589–1681
   PubMed Web of Science ®Google Scholar
• Owen AM, Coleman MR, Boly M, Davis MH, Laureys S, Pickard JD. Detecting awareness in the vegetative state. Science 2006; 313: 1402
   PubMed Web of Science ®Google Scholar
• Fridman EA, Colvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, Leiguarda RC, Zafonte R. Fast awakening from minimally conscious state with apomorphine. Brain Injury 2009; 23: 172–177
   PubMed Web of Science ®Google Scholar
• Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: A SPECT study using 123I-beta-CIT and 123I-IBZM. European Journal of Nuclear Medicine 2000; 27: 1410–1414
   PubMedGoogle Scholar
• Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: Part 1. Journal of Head Trauma Rehabilitation 2000; 15: 1179–1182
   PubMed Web of Science ®Google Scholar
• Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: Part 2. Journal of Head Trauma Rehabilitation 2001; 16: 112–116
   PubMed Web of Science ®Google Scholar
• Haig AJ, Ruess JM. Recovery from vegetative state of six months’ duration associated with Sinemet (levodopa/carbidopa). Archives of Phis Medical Rehabilitation 1990; 71: 1081–1083
   PubMed Web of Science ®Google Scholar
• Krimchansky B-Z, Sazbon L, Groswasser Z. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Injury 2004; 18: 1099–1105
   PubMed Web of Science ®Google Scholar
• Matsuda W, Matsumura A, Komatsu Y, Yanaka K, Nose T. Awakenings from persistent vegetative state: Report of three cases with parkinsonism and brain stem lesions on MRI. Journal of Neurology, Neurosurgery and Psychiatry 2003; 74: 1571–1573
   PubMed Web of Science ®Google Scholar
• Passler M, Riggs R. Positive outcome in traumatic brain injury-vegetative state: Patients treated with bromocriptine. Archives of Physical Medicine Rehabilitation 2001; 82: 311–315
   PubMed Web of Science ®Google Scholar
• Meythaler J, Brunner R, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. Journal of Head Trauma Rehabilitation 2002; 17: 300–313
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clinical Pharmacokinetics 2002; 41: 261–309
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The ‘on-off’ phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. New England Journal of Medicine 1984; 310: 483–488
   PubMed Web of Science ®Google Scholar
• Mawdsley C, Williams IR, Pullar IA, Davidson DL, Kinloch NE. Treatment of parkinsonism by amantadine and levodopa. Clinical and Pharmacological Therapy 1972; 13: 575–583
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: A 3 year follow-up. Journal of Neurology, Neurosurgery and Psychiatry 1989; 52: 773–775
   PubMed Web of Science ®Google Scholar
• Kolls BJ, Stacy M. Apomorphine: A rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clinical Neuropharmacology 2006; 29: 292–301
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Movement Disorders 2005; 20: 151–157
   PubMed Web of Science ®Google Scholar
• Brogden RN, Carmine AA, Heel RC, et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360–400
   Google Scholar
• Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head trauma: Coma to community. Archives of Physical Medicine and Rehabilitation 1982; 63: 118–123
   PubMed Web of Science ®Google Scholar
• Rappaport M, Dougherty AM, Kelting BA. Evaluation of coma and vegetative states. Archives of Physical Medicine and Rehabilitation 1992; 73: 628–634
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: An evidence-based review of its use in Parkinson's disease. Drugs and Aging 2004; 21: 687–709
   PubMed Web of Science ®Google Scholar
• Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. Journal of Neurology 2004; 251: 1370–1374
   PubMed Web of Science ®Google Scholar
• Apokyn package insert. Physicians’ desk reference. Montvale. Thomson PDR, NJ 2006; 2132–2136
   Google Scholar
• Hurst RS, Higdon NR, Lawson JA, et al. Dopamine receptor agonists differ in their actions on cardiac ion channels. European Journal of Pharmacology 2003; 482: 31–37
   PubMed Web of Science ®Google Scholar
• Kaplan M, et al. Asymptomatic interval in delayed traumatic intracerebral hemorrhage: Report of two cases. Clinical Neurology and Neurosurgery 2003; 105: 153–155
   PubMed Web of Science ®Google Scholar
• Agrawal A, Timothy J, Pandit L, Manju M. Post-traumatic epilepsy: An overview. Clinical Neurology and Neurosurgery 2006; 108: 433–439
   PubMed Web of Science ®Google Scholar